Pfizer

The proxy battle between activist Starboard Value and pharmaceutical giant Pfizer has already taken a hostile turn. Anonymous sources have disparagingly suggested that Pfizer CEO Dr. Albert Bourla should be removed. After news reports…

(Reuters) - Pfizer (NYSE:) former CEO and Chairman Ian Read and former CFO Frank D'Amelio said in a statement that they will not partner with activist investor Starboard Value, which wants the US pharmaceutical giant to make…

(Reuters) - Activist investor Starboard Value has taken a stake worth about $1 billion Pfizer (NYSE:) wants the US pharmaceutical giant to make changes to turn around its performance, sources familiar with the matter said on…

Investing.com - U.S. stocks rose sharply on Monday, as traders remained cautious ahead of the Federal Reserve's latest policy meeting. Here are some of the biggest moves in U.S. stocks before the market opens today. Pfizer (NYSE:)…

In the midst of the coronavirus pandemic a few years ago, any positive news from a COVID-19 vaccine or drug developer would have been met with a surge in buying of its shares. But it’s not 2021 anymore, and there’s an encouraging…

JHVEphoto Pfizer has appointed Andrew Baum, head of global health and managing director of equity research at Citi, as its new head of strategy and innovation. Baum, a physician, has been with Citi (C) since 2011. Before joining Citi,…

Weight loss translates into profits for investors. Just look at Eli Lilly And Novo Nordisk. Both stocks have risen dramatically thanks in large part to their obesity drugs, with Lilly's stock more than quadrupling and Novo's…

Pfizer (NYSE:PFE) has sold over £3 billion ($3.8 billion) of shares in Haleon (NYSE:HLN), thereby reducing its interest in the consumer health firm from 32% to approximately 22.6%. The U.S. drugmaker sold around 790.55M Haleon (HLN)…

Pfizer Inc. (NYSE: PFE) is expected to release earnings results for its fourth quarter, before the opening bell on Jan. 30, 2024.Analysts expect the New York-based pharma giant to report quarterly earnings at 22 cents per share, versus…

Pfizer Inc. is dropping development of an experimental weight-loss pill due to side effects, a blow to the drugmaker’s efforts to find new avenues for growth. More than half of patients in a mid-stage study had to stop taking twice-daily…